Collaboration in Healthcare

We view strategic collaborations as integral to transforming the lives of patients with serious medical needs around the world. Together with our partners, we bring healthcare innovations to life.

Healthcare Innovation Starts with Collaboration

If you're searching for a strong partner for your next project, look no further than Merck KGaA, Darmstadt, Germany. Whether it’s an early-stage licensing opportunity, new technology or strategic research alliance, we’re actively seeking partnerships with like-minded organizations – those that value trust, transparency and mutually rewarding relationships, with the ambition to increase the value of each partnership.We are focused on broadening our access to the world of scientific and product innovation beyond our own laboratories, and are interested in extending our global and regional commercial portfolio. If you are looking for a partner either to bring your competitive portfolio of investigational products to the market, or to fully exploit the potential of your commercial products, we’d love to hear from you.

Download the Healthcare Business Development Partnering Brochure

Learn more about our Strategic Focus & Partnerships

Strategy in Action

In order to achieve our strategic business objectives, we are aiming to invest energy and resources in the following partnerships, key franchises and markets.

Building our Bench Strength

For further information in partnering with us, please visit here.

We believe in the innovative power of collaboration. We are actively seeking new strategic partnerships, and will consider all opportunities that have the potential to create value using innovative deal structures and creative alliances. Take a deeper dive into our key areas and partnerships.

Learn more about collaborating with us

Accelerating innovation

We are committed to a collaborative R&D model, forging partnerships with academic, research institutions, and biotech and pharma companies to bring new therapies to patients. With roughly 50% of our pipeline developed through collaborations, we value the innovative spirit that exists both inside our walls and around the ecosystem of healthcare.

Related News

View All News
  1. Press Releases

    New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor ...

    Merck KGaA, Darmstadt, Germany, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating ...


  2. Press Releases

    New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on ...

    Merck KGaA, Darmstadt, Germany today announced new interim real-world data on MAVENCLAD® (cladribine tablets)


  3. Press Releases

    Merck KGaA, Darmstadt, Germany Completes Enrollment of Evobrutinib Phase III ...

    Merck KGaA, Darmstadt, Germany, today announced enrollment has been completed in the Phase III EVOLUTION RMS clinical trial program, which is evaluating the efficacy and safety of investigational ...